参考文献/References:
[1] Zeng T, Cui DM, L Gao. Glioma: an overview of current
classifications, characteristics, molecular biology and target
therapies [J]. Front Biosci (Landmark Ed), 2015, 20: 1104-
1115.
[2] Fojo AT, A Noonan. Why RECIST works and why it should
stay--counterpoint [J]. Cancer Res, 2012, 72(20): 5151-
5158.
[3] Cairncross JG, Eisenhauer EA, Macdonald DR, et al. Phase
II study of trimetrexate in recurrent anaplastic glioma:
National Cancer Institute of Canada Clinical Trials Group
Study [J]. Can J Neurol Sci, 1990, 17(1): 21-23.
[4] van den Bent MJ, Vogelbaum MA, Wen PY, et al. End point
assessment in gliomas: novel treatments limit usefulness of
classical Macdonald's Criteria [J]. J Clin Oncol, 2009, 27
(18): 2905-2908.
[5] Galanis E, Wu W, Cloughesy T, et al. Phase 2 trial design in
neuro-oncology revisited: a report from the RANO group
[J]. Lancet Oncol, 2012, 13(5): e196-204.
[6] Lescher S, Schniewindt S, Jurcoane A, et al. Time window
for postoperative reactive enhancement after resection of
brain tumors: less than 72 hours [J]. Neurosurg Focus,
2014, 37(6): E3.
[7] Huang RY, Neagu MR1, Reardon DA, et al. Pitfalls in the
neuroimaging of glioblastoma in the era of antiangiogenic
and immuno/targeted therapy--detecting illusive disease,
defining response [J]. Front Neurol, 2015, 6: 33.
[8] Butowski N, SM Chang. Endpoints for clinical trials and
revised assessment in neuro-oncology [J]. Curr Opin Neurol,
2012, 25(6): 780-785.
[9] van den Bent MJ, Wefel JS, Schiff D, et al. Response assess-
ment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas
[J]. Lancet Oncol, 2011, 12(6): 583-593.
相似文献/References:
[1]柳 羲 张 帆 田勤力 刘 利.成人幕上原始神经外胚层肿瘤3例报道及文献复习[J].中国临床神经外科杂志,2015,(11):689.[doi:10.13798/j.issn.1009-153X.2015.11.016]
[2]刘 阳 连 伟 综述 王任直 校审.垂体泌乳素腺瘤诊疗中常见问题及解决方案[J].中国临床神经外科杂志,2015,(11):698.[doi:10.13798/j.issn.1009-153X.2015.11.020]
[3]常英男 王 策 赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(06):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[4]吴 亮 黄 玮 余永佳 利文倩 陆 健 林正锋.儿童低级别脑动静脉畸形的治疗[J].中国临床神经外科杂志,2016,(05):294.[doi:10.13798/j.issn.1009-153X.2016.05.012]
[5]杨洪斌 索朗次仁 史 睿 吴京雷.西藏山南地区高血压脑出血的临床特点分析
（附39例报告）[J].中国临床神经外科杂志,2016,(05):300.[doi:10.13798/j.issn.1009-153X.2016.05.015]
[6]敖祥生 胡克琦.血管内治疗椎动脉夹层动脉瘤14例临床分析[J].中国临床神经外科杂志,2016,(05):302.[doi:10.13798/j.issn.1009-153X.2016.05.016]
[7]张 林 综述 殷玉华 审校.脊髓栓系综合征治疗的研究进展[J].中国临床神经外科杂志,2016,(05):310.[doi:10.13798/j.issn.1009-153X.2016.05.020]
[8]郑 涛 赵兰夫 高国栋.多囊肾尿毒症期并发脑出血综合治疗1例[J].中国临床神经外科杂志,2016,(05):320.[doi:10.13798/j.issn.1009-153X.2016.05.024]
[9]许 耿 路俊锋 杨 忠 施建斌 吴秋月 王 烨 庄冬晓 吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[10]李剑峰 陈银生 赛 克 张湘衡 柯 超 杨群英 牟永告 许海雄 陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[11]赵建辉 胡世颉 综述 费 舟 审校.miRNA在胶质瘤临床诊疗中的研究进展[J].中国临床神经外科杂志,2016,(10):642.[doi:10.13798/j.issn.1009-153X.2016.10.029]
[12]杨 雪 杨吉安 综述 陈谦学 审校.Hippo信号通路与胶质瘤的研究进展[J].中国临床神经外科杂志,2017,(04):279.[doi:10.13798/j.issn.1009-153X.2017.04.029]
[13]张 国 综述 易 伟 审校.针对脑胶质瘤相关通路治疗的研究进展[J].中国临床神经外科杂志,2018,(03):215.[doi:10.13798/j.issn.1009-153X.2018.03.028]
[14]程 荆 综述,范燕琴,周 汉,等.TGF-β信号通路在胶质瘤中的作用及分子机制[J].中国临床神经外科杂志,2019,(04):245.[doi:10.13798/j.issn.1009-153X.2019.04.020]